Results 21 to 30 of about 61,173 (287)

Successful Antithrombin Administration in Andexanet Alfa-Associated Heparin Resistance.

Journal of Cardiothoracic and Vascular Anesthesia, 2020
The authors report the case of a patient treated with andexanet alfa who underwent CPB for emergency treatment of a tamponade. The occurrence of severe heparin resistance complicated the intraoperative course. Treatment included the immediate termination
Heleen J.C.L. Apostel, Kristien Winckers, E. Bidar, J. Schreiber   +3 more
semanticscholar   +1 more source

Antithrombin supplementation in adult patients receiving extracorporeal membrane oxygenation

Perfusion, 2020
Introduction: Extracorporeal membrane oxygenation is associated with an increased risk of thrombosis and hemorrhage. Acquired antithrombin deficiency often occurs in patients receiving extracorporeal membrane oxygenation, necessitating supplementation to
Matthew J Morrisette, Amanda Zomp-Wiebe, K. Bidwell, S. Dunn, Michael G Gelvin, Dustin T. Money, Surabhi Palkimas   +6 more
semanticscholar   +1 more source

The Comparison of the Protective Effects of α- and β-Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro

TH Open, 2017
Antithrombin is a promising option for the treatment of sepsis, and vascular endothelium is an important target for this fatal condition. Here, we aimed to evaluate the protective effects of different glycoforms of antithrombin on histone-induced ...
Toshiaki Iba, Tetsuya Sasaki, Kazutoshi Ohshima, Koichi Sato, Isao Nagaoka, Jecko Thachil   +5 more
doaj   +1 more source

Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells

Biomedicines, 2021
Antithrombin, the main physiological inhibitor of the coagulation cascade, exerts anti-tumor effects on glioblastoma multiforme cells. Antithrombin has different conformations: native, heparin-activated, prelatent, latent, and cleaved. The prelatent form
Julia Peñas-Martínez, Ginés Luengo-Gil, Salvador Espín, Nataliya Bohdan, Carmen Ortega-Sabater, Maria Carmen Ródenas, David Zaragoza-Huesca, María José López-Andreo, Carme Plasencia, Vicente Vicente, Alberto Carmona-Bayonas, Irene Martínez-Martínez   +11 more
doaj   +1 more source

Antithrombin Deficiency: Frequency in Patients with Thrombosis and Thrombophilic Families

Acta Medica, 2023
Purpose: Antithrombin (AT) deficiency is a well-known inherited risk factor for venous thromboembolism (VTE). However, F V Leiden and F II20210a mutations have drawn much more attention in the recent years.
Maria Anna Pejková, Eva Ivanová, Petr Sadílek, Radovan Malý, Zuzana Thibaud, Petr Dulíček   +5 more
doaj   +1 more source

Antithrombotic Management during Percutaneous Mitral Valve Repair with the Mitraclip System in a Patient with Heparin-Induced Thrombocytopenia

TH Open, 2018
Interventional cardiology procedures require full anticoagulation to prevent thrombus formation on catheters and devices with potential development of embolic complications.
Francesco Saia, Elena Biagini, Alessandra Berardini, Matteo Chiarabelli, Emanuela Bertolino, Miriam Compagnone, Claudio Rapezzi   +6 more
doaj   +1 more source

Anticoagulation Management and Antithrombin Supplementation Practice during Veno-venous Extracorporeal Membrane Oxygenation

Anesthesiology, 2019
Background: There is a lack of consensus on how to manage anticoagulation during veno-venous extracorporeal membrane oxygenation, including antithrombin monitoring and supplementation.
A. Protti, G. Iapichino, M. Di Nardo, M. Panigada, L. Gattinoni   +4 more
semanticscholar   +1 more source

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

TH Open, 2018
Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab recognizes FIX/FIXa and FX/FXa, a question may arise whether emicizumab competes with ...
Mariko Noguchi-Sasaki, Tetsuhiro Soeda, Atsunori Ueyama, Atsushi Muto, Michinori Hirata, Hidetomo Kitamura, Kaori Fujimoto-Ouchi, Yoshiki Kawabe, Keiji Nogami, Midori Shima, Takehisa Kitazawa   +10 more
doaj   +1 more source

Transient Hemi-Lower Limb Ischemia in the Newborn: Arterial Thrombosis or Persistent Sciatic Artery?

American Journal of Perinatology Reports, 2017
Neonatal thromboembolism occurs with various predispositions and triggers. Early diagnosis of the thrombosis is challenging and essential for the therapeutic interventions.
Makiko Kirino, Masayuki Ochiai, Masako Ichiyama, Hirosuke Inoue, Takeshi Kusuda, Tadamune Kinjo, Masataka Ishimura, Shouichi Ohga   +7 more
doaj   +1 more source

THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents

Haematologica, 2018
Thromboembolism is a serious complication of induction therapy for childhood acute lymphoblastic leukemia. We prospectively compared the efficacy and safety of antithrombotic interventions in the consecutive leukemia trials ALL-BFM 2000 and AIEOP-BFM ALL
J. Greiner, M. Schrappe, A. Claviez, M. Zimmermann, C. Niemeyer, R. Kolb, W. Eberl, F. Berthold, E. Bergsträsser, A. Gnekow, Elisabeth Lassay, P. Vorwerk, M. Lauten, A. Sauerbrey, J. Rischewski, A. Beilken, G. Henze, W. Korte, A. Möricke   +18 more
semanticscholar   +1 more source